Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary

Author:   Institute of Medicine ,  Board on Health Sciences Policy ,  Forum on Drug Discovery, Development, and Translation ,  Anne B. Claiborne
Publisher:   National Academies Press
ISBN:  

9780309253154


Pages:   248
Publication Date:   13 October 2012
Format:   Paperback
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Our Price $129.36 Quantity:  
Add to Cart

Share |

Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary


Add your own review!

Overview

There is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and practical evidence for drug development and to support medical treatment decisions. With the need for transforming the CTE in the U.S. becoming more pressing, the IOM Forum on Drug Discovery, Development, and Translation held a two-day workshop in November 2011, bringing together leaders in research and health care. The workshop focused on how to transform the CTE and discussed a vision to make the enterprise more efficient, effective, and fully integrated into the health care system. Key issue areas addressed at the workshop included: the development of a robust clinical trials workforce, the alignment of cultural and financial incentives for clinical trials, and the creation of a sustainable infrastructure to support a transformed CTE. This document summarizes the workshop. Table of Contents Front Matter 1 Introduction 2 Integrating Community Practice and Clinical Trials 3 Improving Public Participation in Clinical Trials 4 Creating a New Business Model for Clinical Trials 5 Building an Infrastructure to Support Clinical Trials 6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise References Appendix A: Workshop Agenda Appendix B: Participant Biographies Appendix C: Registered Workshop Attendees Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research Appendix I: Discussion Paper: Health Research as a Public Good Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise

Full Product Details

Author:   Institute of Medicine ,  Board on Health Sciences Policy ,  Forum on Drug Discovery, Development, and Translation ,  Anne B. Claiborne
Publisher:   National Academies Press
Imprint:   National Academies Press
ISBN:  

9780309253154


ISBN 10:   0309253152
Pages:   248
Publication Date:   13 October 2012
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

1 Front Matter; 2 1 Introduction; 3 2 Integrating Community Practice and Clinical Trials; 4 3 Improving Public Participation in Clinical Trials; 5 4 Creating a New Business Model for Clinical Trials; 6 5 Building an Infrastructure to Support Clinical Trials; 7 6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise; 8 References; 9 Appendix A: Workshop Agenda; 10 Appendix B: Participant Biographies; 11 Appendix C: Registered Workshop Attendees; 12 Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation; 13 Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce; 14 Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials; 15 Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure; 16 Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research; 17 Appendix I: Discussion Paper: Health Research as a Public Good; 18 Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience; 19 Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List